This is a prospective, open-label, follow up study to protocol 101/2 - continued treatment by IPL344 IV administered once a day in up to 15 participants with ALS. The study is designed to determine the safety, tolerability and initial efficacy of IPL344, administered once a day, by IV infusion for up to 36 months
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
Hadassah Medical Center/Neuromuscular / EMG service and ALS / Motor Neuron Disease Clinic
Jerusalem, Israel
Hadassah Medical Center -Motor Neuron Disease Clinic
Jerusalem, Israel
Adverse Events (AEs) and Serious Adverse Events (SAEs) Reporting
All AEs will be recorded, whether considered minor or serious, drug-related or not
Time frame: upto 36 month
Changes from baseline in ALS disease progression
Evaluated by the Amyotrophic Lateral Sclerosis Functional Rating Scale(ALSFRS-R). The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing
Time frame: upto 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.